ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Status:
Completed
Trial end date:
2008-09-22
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells
and slow the growth of prostate cancer. It is not yet known which dose of ZD 1839 is more
effective in treating prostate cancer that has not responded to hormone therapy.
PURPOSE: Randomized phase II trial to compare different doses of ZD 1839 in treating patients
who have prostate cancer that has not responded to hormone therapy.